Acute Liver Failure, Acute on Chronic Liver Failure, Acute Respiratory Distress Syndrome, Burns, Cardiogenic Shock, Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS), Drug Overdose, Extracorporeal Life Support, Hemophagocytic Lymphohistiocytoses, Infectious Disease, Liver Transplant; Complications, Pancreatitis, Postoperative Endocarditis, Postoperative Vasoplegic Syndrome, Rhabdomyolysis, Sepsis, Septic Shock, Trauma
Conditions
Brief summary
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care
Interventions
DEVICECytoSorb
Sorbent hemoperfusion system
Sponsors
CytoSorbents, Inc
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Planned OR actual CytoSorb® 300 mL device utilization 2. Informed consent for prospective registry participation
Exclusion criteria
1. Use of the CytoSorb® 300 mL device for antithrombotic removal only 2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only 3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ICU mortality | Through ICU discharge or date of death, whichever comes first [on average 7 days] |
| In-hospital mortality | Through hospital discharge or date of death, whichever comes first [on average 14 days] |
Countries
Austria, Germany, Italy, Poland, Portugal, Spain
Contacts
Primary ContactRobert Wilke
Outcome results
None listed